Degrees and Certifications

Degrees

• 2011-2016 - Ph.D., Public Health, Walden University
• 1998-2005 - M.P.H., Wayne State University School of Medicine
• 1979-1981 - Pharm.D., Wayne State University, Pharmacy
• 1976-1979 - B.S., Northeastern University, Boston, Pharmacy
• 1975-1976 - State University College of Buffalo, Buffalo, Biology
• 1973-1975 - Associates Erie Community College, Amherst, Science

Certification

• 2000 - Board Certified Pharmacotherapy Specialist 9/82. Added Qualifications for Infectious Diseases Pharmacotherapy 

Positions and Employment

• 1993-Present - Professor of Pharmacy and Adjunct Professor of Medicine, Wayne State University
• 2008-2011 - Associate Dean for Research, EACPHS, Wayne State University
• 1987-1993 - Associate Professor, EACPHS, Wayne State University
• 1981-1987 - Assistant Professor of Pharmacy Practice 

Awards and Honors

• 2024 - Distinguished Investigator Award
• 2024 - Society of Infectious Diseases Outstanding Mentor Award
• 2022 - Academy of Scholars, Wayne State University
• 2019 - Distinguished Investigator Award, American College of Clinical Pharmacy, Infectious Diseases Practice Network
• 2018 - Charles H. Gershenson Distinguished Faculty Fellows Award, Wayne State University
• 2018 - Van Greene Lecture Award, Mercer University College of Pharmacy 
• 2017 - Fellow Recognition Award, Society of Infectious Diseases Pharmacists
• 2016 - Therapeutics Frontiers Lecture Award, American College of Clinical Pharmacy 
• 2013 - Preceptor for the Outstanding Student Poster Award in Clinical Sciences, Wayne State University
• 2011 - Outstanding Achievement in Clinical Sciences Research Award, Eugene Applebaum College of Pharmacy & Health Sciences
• 2011 - Lead Industry Collaborator Award, Wayne State University
• 2007 - American College of Clinical Pharmacy-Ortho-McNeil Infectious Diseases Fellowship Award
• 2005 - Distinguished Alumni Award, Wayne State University
• 2004 - The Russell R. Miller Award for Recognition of Sustained and Outstanding Contributions to the Literature of Clinical Pharmacy
• 2003 - The Ted Goldberg Prize in Community Health, School of Medicine, Wayne State University
• 2003 - American College of Clinical Pharmacy-Merck Infectious Diseases Fellowship Award
• 2002 - American Society of Health-System Pharmacists, Award for Sustained Literature Contributions to the Pharmacy Literature for ASHP
• 2000 - Impact paper in ID Pharmacists Research Award, Society of Infectious Diseases Pharmacists
• 1997 - Distinguished Faculty Fellowship Award, Wayne State University
• 1996 - Fellow, Infectious Disease Society of America
• 1992 - Wayne State University Career Chair Development Award
• 1992 - R.W. Johnson Research Institute Fellowship Award
• 1991 - Wayne State University Academic Achievement Award for Natural Sciences
• 1991 - American College of Clinical Pharmacy Fellow Recognition Award
• 1990 - Merck Foundation Fellowship Award
• 1990 - The Upjohn Pharmacy Research Award, Michigan Society of Hospital Pharmacists

Professional Memberships

• 2008-Present - European Society of Clinical Microbiology and Infectious Diseases
• 2005-Present - Society of Healthcare Epidemiology of America
• 2003-Present - ASHP Research Foundation
• 2000-Present - Michigan Antibiotic Resistance Committee
• 1998-Present - Alliance for the Prudent Use of Antibiotics
• 1991-Present - Infectious Diseases Society of America
• 1990-Present - Society of Infectious Diseases Pharmacists
• 1990-Present - Michigan Society of Hospital Pharmacists
• 1989-Present - American Society of Microbiology
• 1983-Present - Phi Delta Chi Pharmaceutical Fraternity
• 1982-Present - American College of Clinical Pharmacy
• 1982-Present - American Association of Colleges of Pharmacy
• 1981-Present - Rho Chi Pharmaceutical Honor Society
• 1981-Present - American Society of Health-System Pharmacists
• 1981-Present - Southeastern MI Society of Hospital Pharmacists

Primary Research Interest

• Dr. Rybak’s primary focus of research is antimicrobial pharmacokinetics and pharmacodynamics (PK/PD) and the assessment of infectious diseases health outcomes, including their relationship to bacterial resistance. His most recent work is focused on the laboratory and clinical outcomes assessment of combination therapy for methicillin and vancomycin-resistant Staphylococcus aureus, enterococcus and gram-negative pathogens.

Recent Publications

Co-Authored Chapters (Last 3 Years)

• Morrisette T, Rybak MJ. Detection of VRSA, VISA, and Vancomycin-Heteroresistant Staphylococcus aureus (hVISA). American Society of Microbiology’s Clinical Microbiology Procedures Handbook. Accepted. Anticipated publication date: fall 2022.

Refereed Journals (Last 3 Years)

• Kunz Coyne AJ, Bleick C, Stamper K, Kebriaei R, Bayer AS, Lehman SM, Rybak MJ. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0138823. doi: 10.1128/aac.01388-23. Epub 2024 Feb 20. PMID: 38376187; PMCID: PMC10989002.
   
• Kunz-Coyne AJ, Stamper K, Bleick C, Kebriaei R, Lehman SM, Rybak MJ. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms. Microbiol Spectr. 2024 Feb 27:e0321223. doi: 10.1128/spectrum.03212-23.

• Rebold N, Alosaimy S, Pearson JC, Dionne B, Taqi A, Lagnf A, Lucas K, Biagi M, Lombardo N, Eudy J, Anderson DT, Mahoney MV, Kufel WD, D'Antonio JA, Jones BM, Frens JJ, Baumeister T, Geriak M, Sakoulas G, Farmakiotis D, Delaportas D, Larew J, Veve MP, Rybak MJ. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. Infect Dis Ther. 2024 Mar;13(3):565-579. doi: 10.1007/s40121-024-00933-2. Epub 2024 Mar 1. PMID: 38427289; PMCID: PMC10965835.

• Alosaimy S, Rybak MJ, Sakoulas G. Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry. Lancet Infect Dis. 2024 Mar;24(3):e179-e188. doi: 10.1016/S14733099(23)00432-2. Epub 2023 Oct 23. PMID: 37883984.

• El Ghali A, Kunz Coyne AJ, Lucas K, Tieman M, Xhemali X, Lau S-p, Iturralde G, Purdy A, Holger DJ, Garcia E, Veve MP, Rybak MJ. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiol Spectr. 2024 Jan 11:e0310823. doi: 10.1128/spectrum.03108-23. Epub ahead of print. PMID: 38206034.

• Abdul-Mutakabbir JC, Opoku NS, Tan KK, Jorth P, Nizet V, Fletcher HM, Kaye KS, Rybak MJ. Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii. Antibiotics (Basel). 2024 Jan 4;13(1):47. doi: 10.3390/antibiotics13010047. PMID: 38247606; PMCID: PMC10812597.

• Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB 3rd, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2023 Nov 29:e0235123. doi: 10.1128/spectrum.02351-23. Epub ahead of print. PMID: 38018984.

• El Ghali A, Stamper K, Kunz Coyne AJ, Holger D, Kebriaei R, Alexander J, Lehman SM, Rybak MJ. Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0072823. doi: 10.1128/aac.00728-23. Epub 2023 Oct 25. PMID: 37877697; PMCID: PMC10649104

• Holger DJ, El Ghali A, Bhutani N, Lev KL, Stamper K, Kebriaei R, Kunz Coyne AJ, Morrisette T, Shah R, Alexander J, Lehman SM, Rojas LJ, Marshall SH, Bonomo RA, Rybak MJ. Phage-antibiotic combinations against multidrugresistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models. Antimicrob Agents Chemother. 2023 Oct 19:e0057823. doi: 10.1128/aac.00578-23. Epub ahead of print. PMID: 37855639.

• Kebriaei R, Abdul-Mutakabbir JC, Stamper KC, Lev KL, Rybak MJ. Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin. Infect Dis Ther. 2023 Oct 5. doi: 10.1007/s40121-023-00875-1. Epub ahead of print. PMID: 37798469.

• El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, Wadle C, Philley JV, Mejia-Chew C, Hamad Y, Stevens RW, Zeuli JD, Webb AJ, Fiske CT, Simonyan A, Cimino CL, Mammadova M, Umana VE, Hasbun R, Butt S, Molina KC, Thomas M, Kaip EA, Bouchard J, Gore TW, Howard C, Cabanilla MG, Holger DJ, Frens JJ, Barger M, Ong A, Cohen KA, Rybak MJ. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023 Sep 28:e0082423. doi: 10.1128/aac.00824-23. Epub ahead of print. PMID: 37768312.

• Kunz Coyne AJ, Orzol C, Veve MP, Rybak MJ. Weighing the Odds: Novel βLactam/β-Lactamase Inhibitor Use in Hospital-Acquired and VentilatorAssociated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese. Open Forum Infect Dis. 2023 Aug 28;10(9):ofad454. doi: 10.1093/ofid/ofad454. PMID: 37720698; PMCID: PMC10500045.

• Kunz Coyne AJ, Stamper K, El Ghali A, Kebriaei R, Biswas B, Wilson M, Deschenes MV, Tran TT, Arias CA, Rybak MJ. Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against DaptomycinNonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation Ex Vivo Model. Microbiol Spectr. 2023 Aug 17;11(4):e0034023. doi: 10.1128/spectrum.00340-23. Epub 2023 Jun 20. PMID: 37338375; PMCID: PMC10433949.

• Kebriaei RK, Lehman SM, Shah RM, Stamper KC, Kunz Coyne AJ, Holger D, El Ghali A, Rybak MJ. Phage-antibiotic Combination Optimization against Biofilms of Staphylococcus aureus: Empirical Screening Approach. Spectrum (2023). Accepted for publication.

• El Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. Sulbactam-durlobactam: a novel combination of β-lactamase inhibitors for the treatment of carbapenem-resistant Acinetobacter spp. Infections. Pharmacotherapy (2023).

• Morrisette T, Stamper KC, Lev KL, Kebriaei R, Holger DJ, Abdul-Mutakabbir JC, Kunz Coyne AJ, Rybak MJ. Evaluation of omadacycline alone and in combination with rifampin against biofilm-producing Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy (2023). Accepted for publication.

• Gomes MZR, de Lima EM, Aires CAM, Pereira PS, Yim J, Silva FH, Rodrigues CAS, Oliveira TRT, da Silva PP, Eller CM, de Souza CMR, Rybak MJ, Albano RM, de Miranda AB, Machado E, Catanho M, Nucleus of Hospital Research (NPH) study collaborators. Outbreak report of polymyxin- carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes. Nature, Scientific Reports (2023).

• Mishra N, Abdelhady W, Elsayed A, Lapitan C, Proctor R, Rybak MJ, Miro J, Bayer A. Combinations of Daptomycin Plus Ceftriaxone, but not Ascending Daptomycin Dose-Regimens, are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance. Antimicrobial Agents and Chemotherapy (2023).

• Kunz Coyne Ak, El Ghali A, Lucas K, Witucki P, Rebold N, Holger D, Veve MP, Rybak MJ. High Dose Cefepime Versus Carbapenems for Bacteremia Caused by Enterobacterales with Moderate to High Risk of Clinically Significant AmpC b-Lactamase Production. Open Forum Infectious Diseases (2023).

• Caniff KE, Rebold N, Rybak MJ. Oral stepdown in Gram-positive bloodstream infections: A step in the right direction. Pharmacotherapy (2023). Accepted for publication.

• Rebold N, Lagnf A, Alosaimy S, Holger D, Witucki P, Mannino A, Dierker M, Lucas K, Kunz Coyne AJ, El Ghali A, Caniff K, Veve M, Rybak MJ. Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure. Microbiology Spectrum (2022).

• Kebriaei R, Bayer AS, Lapitan CK, Rybak MJ, Somerville GA, Mishra NK. Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance In Vitro and In an Ex Vivo Model.Antibiotics (2022).

• Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins III NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiology Spectrum (2022).

• Zasowski EJ, Trinh TD, Claeys KC, Dryden M, Shlyapnikov S, Bassetti M, Carnelutti A, Khachatryan N, Kurup A, Pulido Cejudo A, Melo L, Rybak MJ. International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. Infectious Diseases and Therapy (2022).

• Kunz Coyne AJ, Stamper K, Kebriaei R, Holger DJ, El Ghali A, Morrisette T, Biswas B, Wilson M, Deschenes MV, Canfield GS, Duerkop BA, Arias CA, Rybak MJ. Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-embedded Multidrug-resistant Enterococcus faecium with Preserved Phage Susceptibility. Antibiotics (2022).

• Holger D., Rebold N. S., Alosaimy S., Morrisette T., Lagnf A., Belza A. C., Kunz Coyne A. J., El Ghali A., Veve M., Rybak M. J. Impact of Ceftolozane-tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Infectious Diseases and Therapy (2022).

• Blaskovich M.A.T., Hansford K. A., Butler M. S., et al…, Rybak M.J….. Cooper M.A. A Promising Membrane-targeting Lipoglycopeptide Antibiotic to Treat Gram-Positive Biofilm-Related Infections. Science and Translational Medicine.14, eabj2381 (2022).

• Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, et al… Rybak MJ. Nephrotoxicity of Vancomycin in Combination with Beta-lactam Agents: Ceftolozane-tazobactam vs. Piperacillin-tazobactam. Clinical Infectious Disease (2022).

• Holger D, Lev KL, Kebriaei R, Morrisette T, Shah R, Alexander J, Lehman SM, Rybak MJ. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: in vitro synergy testing. Journal of Applied Microbiology (2022).

• Morrisette T, Alosaimy S, Lagnf AM, Frens JJ, Webb AJ, Veve MP, Stevens R, Bouchard J, Gore TW, Ansari I, Rybak MJ. Real-World, Multi-Center Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens. Infectious Diseases and Therapy (2022).

• Rebold N, Alosaimy S, Morrisette T, Holger D, Lagnf AM, Ansari I, Belza AC, Cheaney L, Hussain H, Herbin S, Abdul-Mutakabbir J, Carron C, Sandhu A, Chopra T, Rybak MJ. Clinical characteristics associated with bacterial bloodstream coinfection in COVID-19. Infectious Diseases and Therapy (2022).

• Kebriaei R, Lev KL, Shah RM, Stamper KC, Holger DJ, Morrisette T, Kunz Coyne AJ, Lehman, SM, Rybak MJ. Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination. Microbiology Spectrum (2022).

• Gina A. Suh, Thomas P. Lodise, Pranita D. Tamma, Jane M. Knisely, Jose Alexander, Saima Aslam, Karen D. Barton, Erica Bizzell, Katherine M. C. Totten, Joseph L. Campbell, Benjamin K. Chan, Scott A. Cunningham, Katherine E. Goodman, Kerryl E. Greenwood-Quaintance, Anthony D. Harris, Shayla Hesse, Anthony Maresso, Veronique Nussenblatt, David Pride, Michael J. Rybak, Zoe Sund, David van Duin, Daria Van Tyne, Robin Patel, for the Antibacterial Resistance Leadership Group. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrobl Agents Chemoth, 2022.

• Lev K,. Kunz Coyne AJ, Kebriaei R, Morrisette T, Stamper K, Holger D, Canfield GS, Duerkop BA Arias CA, Rybak MJ. Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-embedded MDR Enterococcus faecium. Antibiotics (2022).

• Dana J Holger, Ashlan J Kunz Coyne, Jing J Zhao, Avnish Sandhu, Hossein Salimnia, Michael J Rybak. Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report, Open Forum Infectious Diseases, 2022;, March 5, 9(4):

• Rebold N, Lodise T, Rybak MJ. Panacea or oversimplification: Relating AUC and troughs. Am J Health Syst Pharm. 2022 Feb 5:zxac031.

• Kunz Coyne, A.J., El Ghali, A., Holger, D. Rebold, N., Rybak, MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther (2022).

Refereed Papers (Year-To-Date)

• Al Musawa M, Kunz Coyne AJ, Witucki P, Althubyni A, Deri C, Wrenn R, Shald E, Rux C, Yost C, Hayes J, Mynatt R, VanDorf S, Bleick C, Slaton C, Judd C, Holger D, Caniff K, Garey KW, Eubank TA, Veve MP, Rybak MJ. Ceftazidime/Avibactam for the Treatment of Infections Caused by MultidrugResistant Gram-Negative Pathogens in Immunocompromised Patients. Presented at th 26th Annual MAD-ID meeting, May 8-11, 2024 in Orlando, Florida.

• Al Musawa M, Vemula R, Mammadova M, Wadle C, Muscarella A, Cimino C, Zeuli J, Howard C, Butt S, Fiske CT, Caniff K, Rybak MJ. Omadacycline as Salvage Therapy for Pulmonary Mycobacterium Abscessus Complex. Presented at th 26th Annual MAD-ID meeting, May 8-11, 2024 in Orlando, Florida.

• Bleick CR, Vader S, Avery S, Yousif P, Hailo J, Lawal A, Chowdhury M, Rybak MJ. Evaluating the Efficacy of Bacteriophage plus Daptomycin and Cefazolin against Methicillin-resistant Staphylococcus aureus (MRSA) Isolates across MHB and RPMI. Presented at th 26th Annual MAD-ID meeting, May 811, 2024 in Orlando, Florida.

• Bleick C, Vader S, Thota N, Avery S, Lehman S, Bayer A, Rybak MJ. Timely tactics: optimizing bacteriophage and antimicrobial efficacy against daptomycin non-susceptible (DNS) and MRSA clinical isolates. Presented at ECCMID, April 27-30, 2024 in Barcelona, Spain. Poster ID P2402.

• Caniff KE, Peitsch C, Al Musawa M, Shupp M, Veve MP, Alangaden G, Walsh TJ, Rybak MJ. Opening the DOOR to Candidemia Diagnostics: A Desirability of Outcomes Ranking Analysis of T2Candida vs. Blood Culture in Critically Ill Patients. Presented at ECCMID, April 27-30, 2024 in Barcelona, Spain. Poster ID 2870.

• Caniff KE, Lucas K, Witucki P, Peitsch C, Veve MP, Rybak MJ. Clinical experience with ceftaroline fosamil in infective endocarditis due to methicillinresistant Staphylococcus aureus. Presented at ECCMID, April 27-30, 2024 in Barcelona, Spain. Poster ID P09663.

Laboratory Web Site

http://cphs.wayne.edu/research/anti-infective-lab.php

Courses taught by Michael Rybak, Pharm.D., M.P.H., Ph.D.

Winter Term 2025 (future)

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

Winter Term 2024

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

Winter Term 2023

• PHA5215 - Principles of Pharmacotherapy IV: Infectious Diseases

← Return to listing